Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 8;1(1):e000042.
doi: 10.1136/rmdopen-2014-000042. eCollection 2015.

Estimating the monetary value of the annual productivity gained in patients with early rheumatoid arthritis receiving etanercept plus methotrexate: interim results from the PRIZE study

Wei Zhang  1 , Nick Bansback  1 , Huiying Sun  2 , Ronald Pedersen  3 , Sameer Kotak  3 , Aslam H Anis  1
Affiliations

Estimating the monetary value of the annual productivity gained in patients with early rheumatoid arthritis receiving etanercept plus methotrexate: interim results from the PRIZE study

Wei Zhang et al. RMD Open. .

Abstract

Objective: To measure and value the impact of combined etanercept (ETN) and methotrexate (MTX) therapy on work productivity in patients with early rheumatoid arthritis (RA) over 52 weeks.

Methods: MTX- and biological-naïve patients with RA (symptom onset ≤12 months; Disease Activity Score based on a 28-joint count (DAS28) >3.2) received open-label ETN50/MTX for 52 weeks. The Valuation of Lost Productivity (VOLP) questionnaire, measuring paid and unpaid work productivity impacts, was completed approximately every 13 weeks. Bootstrapping methods were used to test changes in VOLP outcomes over time. One-year productivity impacts were compared between responders (DAS28 ≤3.2) at week 13 and non-responders using zero-inflated models for time loss and two-part models for total costs of lost productivity.

Results: 196 patients were employed at baseline and had ≥1 follow-up with VOLP. Compared with baseline, at week 52, patients gained 33.4 h per 3 months in paid work and 4.2 h per week in unpaid work. Total monetary productivity gains were €1322 per 3 months. Over the 1-year period, responders gained paid (231 h) and unpaid work loss (122 h) compared with non-responders, which amounted to a gain of €3670 for responders.

Conclusions: This is the first clinical trial to measure and value the impact of biological treatment on all the labour input components that affect overall productivity. Combination therapy with ETN50/MTX was associated with a significant productivity gain for patients with early RA who were still observed at week 52. Over the 1-year treatment period, responders at week 13 suffered significantly less productivity loss than non-responders suggesting this gain was related to treatment response.

Trial registration number: ClinicalTrials.gov number NCT00913458.

Keywords: DMARDs (biologic); Early Rheumatoid Arthritis; Economic Evaluations.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study cohort flowchart. DAS28, Disease Activity Score based on a 28-joint count; VOLP, the Valuation Of Lost Productivity questionnaire.
Figure 2
Figure 2
Plots of 3-month productivity loss and costs at each visit by response at week 13. DAS28, Disease Activity Score based on a 28-joint count.
See this image and copyright information in PMC

References

    1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:269–81. 10.1016/S0889-857X(05)70201-5 - DOI - PubMed
    1. Sokka T, Kautiainen H, Pincus T et al. . Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther 2010;12:R42 10.1186/ar2951 - DOI - PMC - PubMed
    1. Merkesdal S, Ruof J, Schöffski O et al. . Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001;44:528–34. 10.1002/1529-0131(200103)44:3<528::AID-ANR100>3.0.CO;2-U - DOI - PubMed
    1. Ten Klooster PM, Veehof MM, Taal E et al. . Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti-tumour necrosis factor treatment. Ann Rheum Dis 2007;66:1485–90. 10.1136/ard.2007.069765 - DOI - PMC - PubMed
    1. Puolakka K, Kautiainen H, Möttönen T et al. . Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004;50:55–62. 10.1002/art.11436 - DOI - PubMed

Associated data

LinkOut - more resources